PDS Biotechnology Corporation

Clinical trials sponsored by PDS Biotechnology Corporation, explained in plain language.

PDS Biotechnology Corporation PDSB NASDAQ

A clinical-stage biotech developing immunotherapies for cancer and infectious diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1 Terminated 1

Experimental combo targets HPV-Driven head and neck tumors

Disease control Completed

This Phase 2 trial tested a combination of two immunotherapies—PDS0101 and pembrolizumab (Keytruda)—in 95 adults with HPV16-positive head and neck cancer that had returned or spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received b…

Phase 2 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control

Last updated Jun 27, 2026 07:53 UTC

PDS Biotechnology Corporation

Experimental combo targets HPV-Driven head and neck tumors